Drug Profile
Research programme: oral insulin analogues - Novo Nordisk
Latest Information Update: 14 Dec 2020
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Insulins
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 08 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in Denmark (PO)
- 22 Dec 2010 Early research in Diabetes mellitus in Denmark (PO)